Team:Stanford-Brown/HumanPractices/PatentEthics

From 2012.igem.org

(Difference between revisions)
(Patent Ethics)
(Patent Ethics)
Line 20: Line 20:
The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community.
The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community.
 +
 +
[[File:AtAGlance.pdf]]

Revision as of 21:33, 3 October 2012


Patent Ethics

In addition to the Synbio Community’s practical need for a guide to help navigate patent law, we also felt it would be invaluable to invigorate the discussion surrounding the ethics of gene patents. Thus we crafted a gene patent ethics review to complement our more practical guide. This review includes two documents, a full paper on the topic as well as an “at a glance” document for those who want to start thinking about these issues in a less rigorous fashion.

As an introduction, it has been estimated that approximately 20% of the human genome is patented . While this is a generalized statement, most would find this notion, at least in part, unsettling. As synthetic biology is a relatively new field with unprecedented possibilities, indubitably, there is a great debate surrounding gene patenting in moral, practical, and legal domains.

The two documents below seek to elucidate the variety of dilemmas that the synbio-patent interaction has provoked and to hopefully offer some objective commentary and insight for the iGEM and greater synthetic biology community.

File:AtAGlance.pdf